THNR:NYE-Amplify ETF Trust (USD)

ETF | Others |

Last Closing

USD 21.661

Change

-0.33 (-1.52)%

Market Cap

USD 2.82M

Volume

100.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies who are manufacturers in the GLP-1 agonist pharmaceutical business or who enable such business. GLP-1 agonists seek to lower blood sugar levels and reduce appetite and promote fullness, with the ultimate potential for weight loss. The fund is non-diversified.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-21 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
SOJE Southern Company (The) Series ..

-0.37 (-2.10%)

USD 65.72B
SGOV iShares® 0-3 Month Treasury B..

+0.01 (+0.01%)

USD 46.95B
JEPI JPMorgan Equity Premium Income..

-0.38 (-0.67%)

USD 39.24B
JPST JPMorgan Ultra-Short Income ET..

-0.01 (-0.02%)

USD 30.70B
DFAC Dimensional U.S. Core Equity 2..

-0.67 (-1.93%)

USD 29.60B
DTB DTE Energy Company 2020 Series

-0.18 (-1.03%)

USD 26.58B
JAAA Janus Detroit Street Trust - J..

N/A

USD 20.80B
GBTC Grayscale Bitcoin Trust (BTC)

+1.24 (+1.47%)

USD 19.42B
AVUV Avantis® U.S. Small Cap Value..

-2.53 (-2.81%)

USD 14.82B
CGDV Capital Group Dividend Value E..

-0.64 (-1.72%)

USD 14.38B

ETFs Containing THNR

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.94% 24% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.94% 23% F 34% F
Trailing 12 Months  
Capital Gain -14.35% 9% A- 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.35% 6% D- 18% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 2.82M 5% F 2% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.